Prepercutaneous coronary intervention Zalunfiban dose-response relationship to target vessel blood flow at initial angiogram in st-elevation myocardial infarction – A post hoc analysis of the cel-02 phase IIa study

• Published in: The American heart journal 2023-08, Vol.262, p.75-82
• Main Authors: Rikken, Sem A.O.F., Bor, Willem L., Selvarajah, Abi, Zheng, Kai L., Hack, Amy P., Gibson, C. Michael, Granger, Christopher B., Bentur, Ohad S., Coller, Barry S., van ’t Hof, Arnoud W.J., ten Berg, Jurriën M.
• Format: Article
• Language: English
• Subjects: Anticoagulants; Blood clots; Blood flow; Blood platelets; Blood vessels; Cardiovascular disease; Catheterization; Coronary Angiography; Coronary vessels; Glycoproteins; Heart; Heart attacks; Humans; Informed consent; Laboratories; Medical imaging; Myocardial infarction; Myocardial Infarction - diagnostic imaging; Myocardial Infarction - drug therapy; Patients; Percutaneous Coronary Intervention; Perfusion; Pharmacodynamics; Pharmacokinetics; Population; Reperfusion; Sensitivity analysis; ST Elevation Myocardial Infarction - diagnostic imaging; ST Elevation Myocardial Infarction - drug therapy; Thrombosis; Treatment Outcome; Vein & artery diseases
• ISSN: 0002-8703; 1097-6744
• DOI: 10.1016/j.ahj.2023.04.009

Zalunfiban (RUC-4) is a novel, subcutaneously administered glycoprotein IIb/IIIa inhibitor (GPI) designed for prehospital treatment to initiate reperfusion in the infarct-related artery (IRA) before primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction (STEMI). Since GPIs have been reported to rapidly reperfuse IRAs, we assessed whether there was a dose-dependent relationship between zalunfiban treatment and angiographic reperfusion indices and thrombus grade of the IRA at initial angiogram in patients with STEMI. This was a post hoc analysis from the open-label Phase IIa study that investigated the pharmacodynamics, pharmacokinetics, and tolerability of three doses of zalunfiban – 0.075, 0.090 and 0.110 mg/kg - in STEMI patients. This analysis explored dose-dependent associations between zalunfiban and three angiographic indices of the IRA, namely coronary and myocardial blood flow and thrombus burden. Zalunfiban was administered in the cardiac catheterization laboratory prior to vascular access, ∼10 to 15 minutes before the initial angiogram. All angiographic data were analyzed by a blinded, independent, core laboratory. Twentyfour out of 27 STEMI patients were evaluable for angiographic analysis (0.075 mg/kg [n=7], 0.090 mg/kg [n=9], and 0.110 mg/kg [n=8]). TIMI flow grade 2 or 3 was seen in 1/7 patients receiving zalunfiban at 0.075 mg/kg, in 6/9 patients receiving 0.090 mg/kg, and in 7/8 patients receiving 0.110 mg/kg (ptrend = 0.004). A similar trend was observed based on TIMI flow grade 3. Myocardial perfusion was also related to zalunfiban dose (ptrend = 0.005) as reflected by more frequent TIMI myocardial perfusion grade 3. Consistent with the dose-dependent trends in greater coronary and myocardial perfusion, TIMI thrombus ≥4 grade was inversely related to zalunfiban dose (ptrend = 0.02). This post hoc analysis found that higher doses of zalunfiban administered in the cardiac catheterization lab prior to vascular access were associated with greater coronary and myocardial perfusion, and lower thrombus burden at initial angiogram in patients with STEMI undergoing primary percutaneous coronary intervention.